-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 16, the results of the proposed selection of drugs in Hebei Province, which lasted for half a month, were officially announced, with a total of 51 varieties (98 drugs) to be selected, involving 74 manufacturers, including the exclusive anticancer drug elemi injection of CSPC Pharmaceutical Group, rabeprazole sodium for injection for non-medical gastric ulcer treatment drug of Shandong Luoxin Pharmaceutical, and oxacillin sodium for injection of star antibacterial drug of Beite Pharmaceutical
.
According to data from Minai.
com, the total sales of 51 varieties to be selected in public hospitals in Hebei Province in 2021 will be close to 600 million yuan
.
Many provinces and cities have successively included biological drugs, and the centralized procurement of biological drugs has set off another boom; The eighth batch of national procurement is approaching, and the inclusion of biological drugs has also attracted much attention
.
The collection and procurement time is tight, the task is heavy, and the winning rules hide the mystery
The collection and procurement time is tight, the task is heavy, and the winning rules hide the mysterySince October 28, Hebei Provincial Pharmaceutical and Equipment Procurement Center officially issued centralized procurement documents, to November 10 to announce the first year of the agreed purchase volume of varieties, and then to November 16 to announce the results of the proposed selection, the centralized procurement in Hebei Province only lasted half a month, which can be described as "tight time and heavy tasks"
.
Source: Hebei Provincial Pharmaceutical Equipment Procurement Center
From the perspective of collective procurement requirements, the province carries out centralized procurement of 51 varieties, the procurement cycle is 2 years, and the agreed procurement volume is not less than 60% of the actual use of medical institutions in the previous year, and the quality level is not distinguished, but enterprises with high-quality levels such as original research and evaluation are allowed to voluntarily participate in collective procurement
.
If you look closely at the selection rules, you will find that there are hidden secrets
.
According to the requirements of the collective procurement documents:
(1) If there are 1-3 bidders under the same generic name, the 1 with the lowest quotation will obtain the full purchase quantity and be selected exclusively, and there is no dispute
.
②
If there are 4 or more bidders under the same generic name, all the varieties of manufacturers whose prices are not higher than 1.
1 times the lowest price are selected, and the medical institution independently selects and allocates the purchase volume to the selected enterprise drugs
.
This means that medical institutions have a greater right of independent choice, and some barefoot varieties have no previous sales and market reputation foundation, it is difficult to counterattack from them; If barefoot variety companies convince medical institutions to choose, there is also a risk that the previously used and selected companies will also be replaced
.
Therefore, the confirmation of the selected company by the selected medical institution has become the key
of the key.
In addition, compared with the selection threshold of 1.
8 times of chemical drugs, 1.
3 times of insulin and 1.
3~1.
8 times of high-value consumables, 1.
1 times of centralized procurement in Hebei Province can be described as quite low
.
It can be seen that in addition to the price, the product competition of more than 4 enterprises pays more attention to product quality and market reputation
.
(3) For unselected varieties, enterprises can list the network at the lowest price in the country, but they need to be included in the key monitoring
at the same time.
It is worth noting that in order to strengthen the management of collective procurement, Hebei Province has made corresponding restrictions on centralized procurement: for products that meet the conditions and are listed on the network in Hebei, if they do not participate, the qualification
for listing the network will be canceled.
In addition, in the same variety declaration enterprise, the person in charge of the enterprise is the same person or different enterprises with direct holding and management relationships, and they are not allowed to participate in the declaration of the variety at the same time, and the division of the selected enterprises is becoming increasingly strict
.
600 million market pattern reshaping, stone medicine, Luoxin, Beite.
.
.
Successful breakout
.
.
Successful breakout
A total of 37 injections were included in Hebei Province, accounting for more than half, and the remaining 14 were oral preparations
.
Among them, there are 48 chemical drugs, and 3 biological drugs are among them, namely thrombin (topical powder), human growth hormone (injection), human growth hormone (sterile powder for injection).
Selected varieties in Hebei Province
Source: Hebei Provincial Pharmaceutical Equipment Procurement Center, Minai Net Collation
In the catalogue to be selected, there are not only exclusive varieties such as elemi injection, but also national medical insurance varieties such as ranitidine injection and leuprorelin injection, non-medical insurance varieties such as rabeprazole injection and spleen aminopeptide oral powder, as well as potential varieties such as oxacillin injection and piperacillin injection with a terminal sales growth rate of more than four digits in public hospitals in Hebei Province in
2022H1.
Rabeprazole injection is a reversible proton pump inhibitor, which has been approved for production by three domestic enterprises: Jiangsu Aosaicom Pharmaceutical, Nanjing Changao Pharmaceutical and Shandong Luoxin Pharmaceutical
.
According to data from Minai.
com, the terminal sales of the drug in public hospitals in Hebei Province in 2021 exceeded 70 million yuan, and Shandong Luoxin Pharmaceutical accounted for about 20%.
Shandong Luoxin was selected exclusively in this collective procurement, which is expected to further increase its market share
.
In 2021, the brand pattern of terminal rabeprazole injection in public hospitals in Hebei Province TOP3
Source: Competition pattern of drug terminals in public hospitals in key provinces and cities of Minai.
com
Elemi injection is the exclusive anticancer drug of CSPC Pharmaceutical Group, often used in the conventional scheme of radiotherapy and chemotherapy, for lung cancer, liver cancer, bone metastases and other malignant tumors, can enhance the curative effect, reduce the toxic side effects of radiotherapy and chemotherapy, and can be used for interventional, endovascular chemotherapy and the treatment of cancerous pleural ascites, the product potential is full, after the exclusive selection of CSPC, it will continue to consolidate its market dominance
.
Oxacillin injection belongs to "enzyme-resistant penicillin", which has a significant
effect on lung abscess, bone and joint, skin and soft tissue infection.
According to data from Minai.
com, there are currently 20 enterprises approved to produce oxacillin sodium for injection, and a total of 10 enterprises such as Kelun Pharmaceutical, Beite Pharmaceutical, and Sino Pharmaceutical of CSPC Group were selected in Hebei Province, and the competition was the most fierce
.
What the subsequent product market trend will be still to be verified by time
.
Competitive landscape of oxacillin sodium for injection
Source: Minainet new version of the database
According to data from Minai.
com, in the terminals of public hospitals in key provinces and cities, Hebei Province's sales in 2020 and 2021 will be more than
6 billion yuan.
A total of 51 drugs were included in this round of centralized procurement in Hebei Province, and the total sales of public hospital terminals in the province in 2021 were close to 600 million yuan
.
Terminal sales scale of public hospitals in Hebei Province in recent years (: 100 million yuan)
Source: Competition pattern of drug terminals in public hospitals in key provinces and cities of Minai.
com
Biological drugs are gradually introduced, paving the way for the eighth batch of national procurement?
Biological drugs are gradually introduced, paving the way for the eighth batch of national procurement?Recently, the collective procurement of biological drugs in Fujian, Anhui, Hebei and other provinces has appeared, and the entry of biological drugs into centralized procurement has gradually become a hot topic
in the industry.
Since the sudden attack of the sixth batch of national procurement (insulin special) last year, and more and more provincial/provincial and municipal alliances have included biological drugs in the pilot, biological drugs will no longer be a "forbidden area"
for centralized procurement.
The National Health Insurance Administration believes that compared with chemical drugs, biological drugs are not supported by consistent evaluation, the naming is complex and diverse, and the production capacity climbs slowly, so it is particularly important
to adjust the centralized procurement conditions and selection rules.
In the sixth batch of national procurement (insulin special), the National Health Insurance Administration made major changes to the selection rules on the basis of guaranteeing supply, such as all the selection, etc.
, and the sharp price reduction is obviously not its main purpose, the key is to squeeze out some of the inflated prices of drugs and make a pilot for the subsequent collection and procurement of biological drugs, and the rules are more relaxed than chemical drugs
.
Under the established strategy of full coverage of centralized procurement, the gradual inclusion of biological drugs and biosimilars in centralized procurement is already a certainty, and the market competition of multiple products is very sufficient, and it is also possible to include biological drugs and chemical drugs in the eighth batch of national procurement
.
According to incomplete statistics, there are currently 3 varieties of ≥ 4 approved companies for biological drugs, including bevacizumab injection, adalimumab injection and infliximab
for injection.
According to data from Minai.
com, the terminal sales of the above varieties in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as Chinese public medical institutions) exceeded 6 billion yuan, 1 billion yuan and 900 million yuan respectively in 2021
.
With a large market volume and a saturated competitive landscape, these varieties are obviously the first choice for inclusion in the
new round of national procurement.
It is expected to be included in the eighth batch of nationally collected biological drugs
Source: Minainet Comprehensive Database
In addition, the competition pattern of interferon, human growth hormone, human interleukin and other biological drug categories has reached 4 or more, for example, human interleukin-2 for injection has been approved for production of biological drugs from 9 enterprises such as Shenzhen Sinovac Biotechnology, Sihuan Biotechnology, and 3SBio; Human interferon α2b injection has been approved for production of biological drugs from 5 companies: Hyber Biotechnology, Beijing Kaiyin, Ankor Biotechnology, Huaxin Biotechnology and Unnamed Bio.
.
.
The above drug categories are expected to be included in the national procurement in the form of special centralized procurement (such as the sixth batch of insulin centralized procurement
).
The eighth batch of national procurement is about to come out, and which varieties will be included in the final is
still inconclusive.
For biological drugs, there are four main reasons for their high attention: first, there are many innovative drugs or improved new drugs; Second, the price is relatively high; Third, consistency evaluation cannot be carried out; Fourth, in recent years, biological drugs have been a hot spot in research and development, and they are also hot products
in national talks.
